MOLECULAR PARTNERS AG (MOLN) Form 6-K — Jul 20, 2026
Molecular Partners AG has announced the dosing of the first patients in its Phase 2 TACTIC trial, evaluating MP0317 in combination with chemoimmunotherapy for advanced cholangiocarcinoma. The randomized multicenter study aims to recruit 75 patients across nine active sites in France to assess the clinical benefit of adding MP0317 to standard-of-care durvalumab and chemotherapy.
Key figures
- Sites active
- 9
- Target patients
- 75
- Phase 1 patients
- 46
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.